Transplantation for mantle cell lymphoma: is it the right thing to do?

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn 2013, Issue , 2013, Pages 568-574

  Williams, Michael E ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; PREDNISONE; PROTEASOME INHIBITOR; R CHOP PROTOCOL; R-CHOP PROTOCOL; TUMOR MARKER; VINCRISTINE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MANTLE CELL LYMPHOMA; METABOLISM; MINIMAL RESIDUAL DISEASE; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, MANTLE-CELL; NEOPLASM, RESIDUAL; PREDNISONE; PROTEASOME INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE;

EID: 84904523445     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2013.1.568     Document Type: Review

References (0)